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Cell-mediated immunity in recent-onset type 1 diabetic children  
 
INTRODUCTION 
Type 1 diabetes mellitus (T1DM) arises from 
selective progressive immunologically mediated 
destruction of the insulin-producing beta-cells in 
the pancreatic islets of Langerhans with consequent 
insulin deficiency.1 Cell mediated immunity has 
been implicated in the pathogenesis of type 1 
diabetes, auto-reactive T-cells that recognize islet 
auto-antigens have been identified and are thought 
to play a direct role in T1DM immuno-
pathogenesis.2 A proposal supported by studies 
showing that administration of therapeutic agents 
that inhibit T-cell function delay disease 
progression in patients of type one diabetes. It is 
critical to note that auto-antibodies have no known 
etiologic role in diabetes and –simply put- are 
believed to represent the "smoke of the fire" in the 
pancreas and not the fire itself.3   
Despite the understanding that type 1 diabetes 
pathogenesis is mediated by certain T-cells, 
detection of these specific T-lymphocyte subsets 
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remains largely elusive. Suitable T-cell assays are 
highly needed, since they could offer preclinical 
diagnosis and immune surrogate end points for 
clinical trials. Although CD4+ T-cell assays have 
met with limited success, CD8+ T-cells are 
increasingly recognised as key factors in the 
diabetes of the non-obese diabetic (NOD) mouse. 
CD8+ T-cells are likely to play a role also in 
humans and may provide new markers of beta-cell 
autoimmunity.4  
T-cell tolerance is established centrally in the 
thymus and further strengthened and maintained 
through multiple mechanisms of peripheral 
tolerance.5 The manifest lack of self tolerance to 
beta-cell autoantigens in patients of type 1 diabetes 
compared with their non-diabetic counterparts 
therefore could be due, at least in part to a failure in 
one or more of these mechanisms. So recent interest 
has focused on a feature of tolerance that seems to 
bridge the central and peripheral processes, namely 
the CD4+, CD25+ regulatory T-cell.5,6 These cells 
represent a naturally occurring CD4+ T-cell 
population expressing CD25 that arises from the 
thymus and seeds into the periphery, creating a 
cohort of cells with profound T-cell immuno-
supressive qualities. These cells can be detected in 
peripheral blood in humans and are able to suppress 
proliferation and cytokine production from both 
CD4+ and CD8+ T-cell in vitro in a cell-contact 
dependent manner. So a relative defect in terms of 
number or function, of these regulatory T-cells 
could contribute to the lack of self tolerance seen in 
patients of type 1 diabetes.1,7 
 The initiation of T1DM appears to require 
cooperation between CD4+ and CD8+ T-cells, with 
CD4+ T-cells playing a key role in islet beta-cell 
destruction.8 Yet, neither in humans nor in NOD 
mice have the immunological requirements for 
diabetogenic CD8 T-cells been precisely defined.9 
Pancreatic lymph node-derived CD4+ CD25+ T-reg 
cells were found to inhibit in situ differentiation of 
islet-reactive CD8+ T-cells into cytotoxic T-
lymphocytes, thereby can help in preventing 
diabetes progression.10 The capacity of pancreatic 
lymph node (PLN) derived T-reg cells to regulate is 
dependent on TNF-related activation induced 
cytokine-receptor activator of NF Kappa B signals. 
Blocking of this pathway results in decreased 
frequency of CD4+ CD25+ T-reg cell in PLN, 
resulting in intra-islet differentiation of CD8+ T-
cells into cytotoxic T-lymphocytes and rapid 
progression to diabetes.11 CD8+ CD25+ T-reg cells 
are suppressor regulatory cells that require cell to 
cell direct contact for inhibition.12 Hence, this study 
was designed to assess the cellular immune 
parameters including the percentage of CD4+, 
CD8+, CD4+ CD25+ and CD8+ CD25+ T-
lymphocytes in the peripheral blood in recent-onset 
type 1 diabetic children. This may possibly have its 
application in developing immune-therapy based 
tools for halting disease progression. 
 
METHODS 
Subjects: The present study was carried out at the 
Diabetes and Outpatient Clinics of Ain Shams 
University Children's Hospital, Cairo, Egypt, during 
the period from September 2006 till June 2007.    
Patients' group: Comprised 20 patients with recent 
onset T1DM diagnosed within less than 6 months. 
They were randomly selected. They comprised 10 
males and 10 females (ratio 1:1), with a mean age 
of 7.8 ± 3.5 years and a range of 4- 12 years. 
Patients were labelled to have T1DM on solid 
clinical grounds (ISPAD clinical practice 
guidelines, 2006/2007) i.e.:  
1 Have age at onset of disease of 4-12 years. 
2 Present with a dramatic classic triad of 
polyuria, polydipsia, and weight loss. 
3 Present with ketoacidosis or ketonuria. 
4 Require insulin to prevent metabolic 
deterioration with ketosis and ketoacidosis (i.e. 
are insulin dependent). 
Control group: Comprised 10 healthy children. 
They served as controls. They comprised 6 males 
and 4 females at a ratio (3:2). They had a mean age 
of 5.5 ± 2.1 years with a range of 3-8 years. 
 
Study measurements: The patients’ group was 
subjected at diagnosis to detailed history taking, 
thorough clinical examination and laboratory 
investigations which included:  
1. Complete blood picture by Beckman Coulter 
Gen. S system. 
2. Blood chemistry including serum creatinine, urea 
and liver enzymes: ALT, AST by Synchron CX9 
(Brea, California, USA) . 
3. Lipid profile evaluation: serum total cholesterol 
(TC) and serum Triglycerides (TG) by Synchron 
CX9 (Brea, California, USA).  
4. Assessment of HbA1c% after three months of 
start of treatment. It was assessed by high 
performance liquid chromatography technique. 
5. Determination of the percentage of surface 
expression of CD4+, CD8+, CD4+ CD25+ and 
CD8+ CD25+ T-lymphocytes in the peripheral 
blood by flowcytometry, where two ml of venous 
blood were drawn from each patient and control 
subject into a tube containing K-EDTA as an 
anticoagulant. The monoclonal antibodies used 
included, CD4 florescenisothiocynat, “FITC”, 
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labelled, CD8 phycoerythrin, “PE”, labelled, 
CD25 allophycocyanin “APC”, labelled. Isotypic 
negative controls FITC, PE and APC, labelled 
were used to determine the non specific bridging. 
For each sample, one assay and one control tube 
were used. Fifty µL of whole blood were 
delivered in each tube, then five µL of 
monoclonal antibodies and isotypic controls were 
added in the test tube and the control tube 
respectively. The tubes were gently vortexed and 
incubated for 15 min at room temperature in the 
dark; cells were then washed in phosphate 
buffered saline (P.B.S). Stained samples were 
then treated with lysing solution (NH4CL 
buffered with KHCO3 at pH 7.2), by adding 1.5 
ml of it in each tube then incubated for 1-2 min at 
37°C. The tubes were washed again prior to flow 
cytometric analysis. Analysis was done on a flow 
cytometer (coulter electronics Epics -XL-FI-
USA) equipped with 480 nm air cooled Argon 
Laser. The percentage of single and double 
positivity stained cells were determined, data was 
plotted on four histograms. The first histogram 
was based on forward scatter versus side scatter 
where lymphocytes were gated. The second 
histogram measures the percentage of expression 
of CD4+, and CD8+ (dual analysis). The third 
histogram measures the percentage of CD8+, 
CD25+ percent expression. The fourth histogram 
measures the percentage of CD4+, CD25+ percent 
expression.  
Statistical Methods: 
Analysis of data was done on an IBM computer 
system using SPSS (statistical program for social 
science) software. All numeric variables were 
expressed as mean ± standard deviation (SD), Chi-
square test was used to compare qualitative 
variables, Mann Whitney Willcoxon U test and 
Unpaired t-test  were used to compare quantitative 
variables (the latter for independent variables) and 
Spearman correlation test was used to rank different 
variables against each other. A p-value of <0.05 
was considered significant and p-value <0.01 was 
considered highly significant. 
 
RESULTS 
Both patients and control groups were comparable 
as regard age, sex and body mass index (BMI). The 
patients group had within normal mean of all 
studied parameters apart from high glycosylated 
hemoglobin (HbA1c), (8.3 ± 1.27), [Table 2]. 
Results of flow cytometry analysis were expressed 
as the percentage of CD4+ T-cells, CD8+ T-cells 
and the percentage of the CD4+ T-cells 
coexpressing CD25 and the CD8 T-cells which 
coexpress CD25. There were no significant 
differences in the percentage of CD4+ lymphocyte 
or CD4+/CD8+ ratio in patients group (mean ± SD, 
33.4 ± 7.2 and 1.7 ± 0.8, respectively) in 
comparison with control subjects (32.28 ± 12.2 and 
1.2 ± 0.6), [Table 3]. 
Also, we found no statistically significant 
difference in the percentage of CD4 lymphocytes 
that coexpress CD25 in the patients group (2.9 ± 
0.74) when compared with control group (2.77 ± 
1.5). Furthermore, there was no significant 
difference between the two groups in the level of 
CD25 expression per cell, when expressed as the 
mean fluorescence intensity (MFI) of the CD4+ 
CD25+ cell population. The MFI of patients was 
(4.1 ± 0.9) and of control subjects was (3.7 ± 0.8).  
A significantly low percentage of CD8+ T-
lymphocytes (22.1 ± 6.8) was found in the patients 
group as compared to the control group (30.6 ± 
9.8), (P<0.01). Moreover, there was statistically 
significant difference in the percentage of CD8+ 
lymphocytes that express CD25 in patients of type 
1 diabetes i.e. patients group (0.35 ± 0.31) as 
compared with control subjects (0.74 ± 0.87), 
[Table 3]. 
There was also statistically significant 
difference between the two groups in the level of 
CD25 expression per cell, when expressed as MFI 
of the CD8+ CD25+ cell population (38.6 ± 5.1) in 
patients with type 1 diabetes and (19.1 ± 2.1) in 
controls, [Table 3]. 
On correlating HbA1c values with the 
percentage of CD parameters, a significant inverse 
correlation was found between the level of HbA1c 
and the percentage of CD4+ CD25+ lymphocytes, 
but there were no significant correlations between 
the level of HbA1c and the percentage of CD4+ , 
CD8+ or CD8+ CD25+ lymphocytes [Table 4]. 
When patients with HbA1c value less than 8% 
and those with HbA1c value more than or equal to 
8% were compared as regard the percentage of 
CD4+, CD8+, CD4+ CD25+ and CD8+ CD25+ 
lymphocytes, a significant high level of CD4+ 
CD25+ lymphocyte percentage was found in 
patients with HbA1c value less than 8% (i.e. of 
good glycemic control). However, there were no 
statistical significant difference between both 
groups (<8%, ≥8% HbA1c) as regard the other CD 
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Table 1. Comparison between patients and controls as regards clinical characteristics. 
 




Age (yrs) 7.8 ± 3.5 5.5+2.1 t=1.9 >0.05 
Gender     
           Males 






Duration of illness (Weeks) 5.4 ± 6.9 - - - 
BMI 19 ± 4.6 20.8+3.8 t=1.05 >0.05 
BMI: Body mass index  P< 0.05: Significant test 
 
 
Table 2. Description of different laboratory data of the studied patients. 
 
Variables Mean+SD 
RBCs (Million/cmm) 4.14 ± 0.7 
Hb  gm/dl 11.9 ± 1.5 
TLC x 103/cmm 7.7 ± 2.7 
Platelets x 103/cmm 337.8 ± 98.9 
Serum creatinine (mg/dl) 0.56 ± 0.26 
ALT   (IU/L) 22.9 ± 12.9 
HbA1c.   (%) 8.3 ± 1.27 
Serum cholesterol (mg/dl) 140.6 ± 46 




Table 3. The studied CD markers in patients and control groups. 
 
Variables Patients Mean±SD 
Controls 
Mean ±SD t P 
CD4+ (%) 33.4 ± 7.2 32.28 ± 12.2 0.31 >0.05 
CD8+ (%) 22.1 ± 6.8 30.6 ± 9.8 2.8 <0.01** 
CD4+CD25+% 2.9 ± 0.74 2.77 ± 1.5 0.24 >0.05 
CD8+CD25+% 0.35 ± 0.31 0.74 ± 0.87 2.1 <0.05* 
CD4+/CD8+% 1.7 ± 0.8 1.2 ± 0.6 1.3 >0.05 
CD4+ CD25+ MFI 4.1 ± 0.9 3.7 ± 0.8 0.32 >0.05 
CD8+ CD25+ MFI 38.6 ± 5.1 19.1 ± 2.1 2.3 <0.05 




Table 4. The studied CD parameters and glycemic control among patients 
 
HbA1c   % Variables r P 
CD4+% -0.027 >0.05 
CD8+% 0.08 >0.05 
CD4+/CD25+% -0.54 <0.05* 
CD8+/CD25% -0.14 >0.05 
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Table 5. Glycemic control and different CD markers. 
 





CD4+% 33 ± 8.7 33.8 ± 5.5 >0.05 0.24 
CD8+% 22.8 ± 7.5 21.3 ± 6 >0.05 0.4 
CD4+CD25+% 2.5 ± 0.6 3.2 ± 0.7 <0.05* 2.3 
CD8+CD25+% 0.29 ± 0.2 0.42 ± 0.4 >0.05 0.9 




Figure 1. Scatter diagram showing inverse correlation between HbA1c and 




In this study we aimed to assess percentage of cells 
thought to be involved in the autoimmune cell-
mediated destruction of pancreatic β cells in the 
peripheral blood of recent onset type 1 diabetic 
children. We chose patients with recent onset type 1 
diabetes, since most of them have ongoing insulitis. 
As shown in table (3), we found no statistically 
significant difference in the percentage of CD4+ T-
lymphocytes in the peripheral blood between the 
patient (33.4 ± 7.2) and control groups (32.28 ± 
12.2, p>0.05).  This finding is in agreement with 
that of Milicevic et al.13, who studied β cell 
secretory function and percentage of different T-
lymphocytes in the patients of early stage of type 1 
diabetes mellitus (T1DM). They also found no 
statistically significant difference between patients 
(42 ± 9.4) and controls (44 ± 7.3) as regards the 
percentage of CD4+ cells (p>0.05). One possible 
explanation for this finding could be the shift of 
these cells from peripheral blood to pancreatic islet 
lymph nodes before disease onset to exert their 
action.14  
In our study we also found that the percent of 
CD4+ CD25+ T reg cells did not show any 
significant difference between patients and controls 
(2.9 ± 0.74 in the patient group versus 2.77 ± 1.5 in 
control group, p>0.05). There are several published 
reports analyzing peripheral blood CD4+ CD25+ T-
reg frequency and function in patients with T1DM. 
Kukreja et al.15 found reduced T reg frequency, 
Lindley et al.16 and Brusko et al.17 found reduced T 
reg function, while Putnam et al.18 did not find any 
significant change as compared to healthy controls.. 
Our finding was in agreement with the results of 
other investigators 16,19, who found no significant 
abnormality in either the number of CD4+/CD25+ 
T-cell or the level of CD25 expression in patients of 
T1DM. This finding contrasts with an earlier 
published report suggesting that expression of 
CD25 is elevated in patients with T1DM,19 and 
another study demonstrating a decrease in CD25 
expression on CD4T-cells.15 Also, our findings 
were in agree with observations published by Gessl 
and Waldhausl.20  
Factors that could account for these differences 
among studies include the definition of CD25+ 
cells, disease duration, and most importantly, 
appropriate matching for age and HLA-type in 
control population. As CD25 is expressed by both 
activated and regulatory T-cells, so careful 
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cell type that negatively regulates other immune 
effectors is difficult to identify with precision at the 
single cell level. For this reason, the identification 
of a phenotype, CD25 positivity which defines a 
population of cells with regulatory properties both 
in vivo and in vitro, has been heralded as an 
important advance.6,21  
CD4+ CD25+ T-reg cells are suppressor cells 
(suppress CD8+ cytotoxic T cells) so they are 
actually expected to decrease in T1DM. Significant 
inclusion of other cells such as recently activated 
CD4+ pathogenic T-cells in the analyzed sample as 
they also fall in this phenotypic subset (T-reg cells) 
may alter the results. Only T-reg cells express the 
transcription factor fork head box protein 3 
(Foxp3). Recent studies suggest that almost half of 
the bulk of CD4+CD25+ T cells detected in humans 
do not express Foxp3 (the gene responsible for 
differentiation of T-reg cells) when the gate is set to 
include the top 10–15% of the CD25+ cells. Even 
when the top 5% of the CD25+ cells are gated, 
significant contamination with Foxp3– cells is still 
present in some samples. The top 2% CD25 bright 
gate most reliably identifies a highly enriched 
Foxp3+ population, but significantly underestimates 
the frequency of Foxp3+ cells in most individuals.12 
Therefore, the use of more markers such as Foxp3 
may increase the specificity of detection of only 
CD4+CD25+ T-reg cells and alter results.  
Our findings corroborate with similar studies in 
other autoimmune conditions such as multiple 
sclerosis and autoimmune polyglandular syndrome 
type II, which also report a defect in 
CD4+/CD25+cell function and not the number of 
this type of cells.22,23 Taken together these studies 
may point to a central role for this regulatory cell 
population in the development of a wide range  of 
autoimmune conditions.                                 
A significantly lower percentage of CD8+ T-
lymphocytes as compared to controls (22.1± 6.8 
versus 30.6± 9.8) p<0.01 was found. This finding 
was  in agreement with Avanzini et al.14, who 
studied the percentage of the CD4+ and CD8+ T-
cells in T1DM at disease onset and after 15 months 
and eight years. They too found lower percentage of 
peripheral CD8+ cells at onset of disease as 
compared to controls. They suggested that this may 
reflect the initial decrease in cytotoxic T cells in the 
blood which occurs as these cells migrate to the 
pancreatic islets where the destruction is occurring 
(starting from the phase of insulitis before disease 
onset). In fact Wong et al.24, studied the structural 
and functional relationships of autoantigenic 
peptides of insulin that stimulate CD8+ T-cells in 
T1DM. They showed that CD8+ T-cells recognizing 
insulin B15-23 peptide are present in the very early 
phases of insulitis. CD8+ T-cells were seen to be 
predominant in islets and low in peripheral blood in 
patients with newly diagnosed diabetes who 
underwent pancreatic biopsy. 25 
It has reported that untreated acute diabetes 
causes rapid lymphopenia followed by homeostatic 
T-cell proliferation. This diabetes induced 
lymphopenia was associated with an immuno-
suppressed state that could be sufficiently strong to 
allow engraftment of fully allogenic beta cells or 
block rejection of islet transplants.26 
The finding of significantly lower percentage of 
CD8+ T-lymphocytes as compared to controls in 
this study came in disagreement with the work of 
Milicevic et al.13, found no difference between 
diabetics and controls as regards percentage of the 
CD8+ T-cells. We can attribute the difference 
between our study and theirs to the difference in 
timing of the study in relation to the time of 
diabetes diagnosis. Most blood samples in our 
patients were taken within days to weeks of initial 
presentation with diabetic ketoacidosis (DKA) at 
disease onset (mean disease duration in our study                   
5.4 + 6.9 weeks) while in Milicevic et al.13 study, 
they were taken over a period of several months (6 
months) respectively.  
Also, we found that the percentage of 
CD8+CD25+ T-lymphocytes was significantly lower 
in the peripheral blood among patients as compared 
to controls (0.35 ± 0.31% versus 0.74 ± 0.87%, 
respectively, p<0.05).These cells are suppressor 
cells that act by direct cell to cell contact in the 
pancreatic islets so they leave the peripheral blood 
to pancreatic islets to exert their effect.12 Bisikirska 
et al.27 studied T-cell receptor (TCR) stimulation 
with modified anti-CD3 monoclonal antibodies in 
patients with T1DM. They too, documented in their 
study a low percentage of CD8+CD25+ T-cells in 
patients with recent onset T1DM and an increase in 
this percentage after stimulation with anti CD3 
monoclonal antibodies. This decrease in CD8+ 
CD25+ may be due to firstly the fact, that although 
both CD4+ CD25+ and CD8+ CD25+ are regulatory 
cells CD8+ CD25+ T-reg cells act by direct cell to 
cell contact so their action is exerted within the 
lymph nodes at the islets of pancrease.12 Secondly, 
the CD8+ markers is expressed only on the surface 
of natural killer cells in addition to cytotoxic T-cells 
as compared to CD4+ which is expressed on many 
cells.28 Moreover, the number of CD4+ T-cells 
normally is double that of CD8+ T-cells, so any 
decrease in the percentage of CD8+ CD25+ T-cells 
will have more reflection on the assayed percentage 
than that of CD4+ CD25+ T-cells. In fact in our 
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study CD4+/CD8+ ratio showed a mild, though non-
significant increase.  
As evident from table (4), a positive inverse 
correlation was found between the degree of 
glycemic control (as reflected by decreased levels 
of HbA1c) and the percentage of CD4+ CD25+ T-
lymphocytes but not with the percentage of other 
CD parameters (CD4+, CD25+ and CD25+) among 
the studied the patient. This means that the higher 
the level of CD4+ CD25+ T-cells the patient had, the 
lower was his HbA1c% after 3 months and vice 
versa. Furthermore, HbA1c value below 8% was 
associated with a higher percentage of CD4+, 
CD25+ T-cells when compared with HbA1c value 
of more than or equal to 8% and a significant 
statistical difference was found as regards the 
HbA1c value and percentage of CD4+, CD25+  T-
cells, (P<0.05). This may be due to the fact that 
CD4+ CD25+ T-cells are regulatory cells which can 
inhibit in situ differentiation of islet-reactive CD8+ 
T-cells into cytotoxic T-lymphocytes (that are 
responsible for beta cells destruction), so the higher 
the percentage of CD4+ CD25+ T-cells, the more the 
preserved well functioning beta cells, the better the 
control of the disease, and consequently the better 
the glycemic control as compared to those with a 
lower percentage of CD4+ CD25+ T-reg cells.10 
Another study14, found no correlation between the 
percentage of various cells and the HbA1c level. 
Yet, in their study the HbA1c together with the cell 
quantitation were done together at diagnosis, then 
after 15 months and after 8 years of disease onset. 
In our study cell assay was done at disease onset 
and the HbA1c assessment was carried after 3 
months to have a better idea about disease control.  
So, in interpreting and comparing results one 
should keep in mind the fact that the percentage of 
various cells changes with time.29  
To conclude T1DM as an autoimmune disease, 
is characterized at its onset by a lower percentage of 
CD8+ T-cells, a lower CD8+ CD25+ in the 
peripheral blood, and a normal percentage of CD4+ 
T-cells. There is a close inverse correlation between 
the percentage of CD4+ CD25+ T-cells at disease 
onset and the HbA1c value after 3 months. 
Suggesting a beneficial role for the early use of 
immunomodulation in halting the progression of the 
disease. Evaluation of the various T-cell subsets 
(CD4+, CD8+, CD4+ CD25+ and CD8+ CD25+ T-
cells) in patients at risk for developing of type 1 
diabetes together with using of more specific 
monoclonal antibodies as FOXP3 for detection of 
CD25+ T-cells seems worthwhile. It would give a 
better insight on the future development of diabetes. 
This, together with the use of specific monoclonal 
antibodies against cells involved in the 
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